{"entity":{"id":"ubx-306","kind":"drug","name":"UBX-306","aka":[],"tldr":"UBX-306 is an experimental not disclosed from Ubix Therapeutics, at a stage the company does not state for cancer.","summary":"UBX-306 is a not disclosed (company platform is targeted protein degraders) from Ubix Therapeutics. Undisclosed immuno-oncology programme; the company names no target. The company does not state its stage; it is aimed at cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Listed on the company pipeline; the stage bar is graphical and not readable in page text. No registered trial found on ClinicalTrials.gov. It has not been shown to work in people.","asOf":"2026-11-03","links":[{"label":"Ubix Therapeutics: ubixtrx.com","url":"https://ubixtrx.com/pipeline"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ubix-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"UBX-306","modality":"Not disclosed (company platform is targeted protein degraders)","mechanism":"Undisclosed immuno-oncology programme; the company names no target.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ubx-306/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"ubix-therapeutics","kind":"company","name":"Ubix Therapeutics","route":"/companies/ubix-therapeutics/"}]}}